|
1
|
Kyriazanos ID, Stamos NP, Miliadis L,
Noussis G and Stoidis CN: Extra-mammary Paget's disease of the
perianal region: A review of the literature emphasizing the
operative management technique. Surg Oncol. 20:e61–e71. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parker LP, Parker JR, Bodurka-Bevers D,
Deavers M, Bevers MW, Shen-Gunther J and Gershenson DM: Paget's
disease of the vulva: Pathology, pattern of involvement, and
prognosis. Gynecol Oncol. 77:183–189. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tokuda Y, Arakura F and Uhara H:
Combination chemotherapy of low-dose 5-fluorouracil and cisplatin
for advanced extramammary Paget's disease. Int J Clin Oncol.
20:194–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tanaka R, Sasajima Y, Tsuda H, Namikawa K,
Tsutsumida A, Otsuka F and Yamazaki N: Human epidermal growth
factor receptor 2 protein overexpression and gene amplification in
extramammary Paget disease. Br J Dermatol. 168:1259–1266. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ogawa T, Nagashima Y, Wada H, Akimoto K,
Chiba Y, Nagatani T, Inayama Y, Yao M, Aoki I and Ikezawa Z:
Extramammary Paget's disease: Analysis of growth signal pathway
from the human epidermal growth factor receptor 2 protein. Hum
Pathol. 36:1273–1280. 2005.PubMed/NCBI
|
|
6
|
Kang Z, Zhang Q, Zhang Q, Li X, Hu T, Xu
X, Wu Z, Zhang X, Wang H, Xu J, et al: Clinical and pathological
characteristics of extramammary Paget's disease: Report of 246
Chinese male patients. Int J Clin Exp Pathol. 8:13233–13240.
2015.PubMed/NCBI
|
|
7
|
Richter CE, Hui P, Buza N, Silasi DA,
Azodi M, Santin AD, Schwartz PE and Rutherford TJ: HER-2/NEU
overexpression in vulvar Paget disease: The Yale experience. J Clin
Pathol. 63:544–547. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keatings L, Sinclair J, Wright C, Corbett
IP, Watchorn C, Hennessy C, Angus B, Lennard T and Horne CH:
c-erbB-2 oncoprotein expression in mammary and extramammary Paget's
disease: An immunohistochemical study. Histopathology. 17:243–247.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Plaza JA, Torres-Cabala C, Ivan D and
Prieto VG: HER-2/neu expression in extramammary Paget disease: A
clinicopathologic and immunohistochemistry study of 47 cases with
and without underlying malignancy. J Cutan Pathol. 36:729–733.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wakabayashi S, Togawa Y, Yoneyama K,
Suehiro K, Kambe N and Matsue H: Dramatic cinical response of
relapsed metastatic extramammary Paget's disease to trastuzumab
monotherapy. Case Rep Dermatol Med. 2012:4013622012.PubMed/NCBI
|
|
11
|
Barth P, Dulaimi Al-Saleem E, Edwards KW,
Millis SZ, Wong YN and Geynisman DM: Metastatic extramammary
Paget's disease of scrotum responds completely to single agent
trastuzumab in a hemodialysis patient: Case report, molecular
profiling and brief review of the literature. Case Rep Oncol Med.
2015:8951512015.PubMed/NCBI
|
|
12
|
Karam A, Berek JS, Stenson A, Rao J and
Dorigo O: HER-2/neu targeting for recurrent vulvar Paget's disease
A case report and literature review. Gynecol Oncol. 111:568–571.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanawa F, Inozume T, Harada K, Kawamura T,
Shibagaki N and Shimada S: A case of metastatic extramammary
Paget's disease responding to trastuzumab plus paclitaxel
combination therapy. Case Rep Dermatol. 3:223–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takahagi S, Noda H, Kamegashira A,
Madokoro N, Hori I, Shindo H, Mihara S and Hide M: Metastatic
extramammary Paget's disease treated with paclitaxel and
trastuzumab combination chemotherapy. J Dermatol. 36:457–461. 2009.
View Article : Google Scholar : PubMed/NCBI
|
